Delivering enhanced cardiovascular disease and hypertension care through private health facilities in Pakista

Completed

• Conditions: Hypertension / Cardiovascular Disease; Circulatory System; Atherosclerotic cardiovascular disease

• Registration Number: ISRCTN34381594
• Lead Sponsor: niversity of Leeds (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07-26
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 912

Inclusion Criteria

1. All newly diagnosed hypertensive (systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg)
2. Male and female patients aged 25 years or more from the catchment population of the respective facility

Exclusion Criteria

1. Pregnant women
2. Persons with advanced chronic disease
3. Person with conditions that cause secondary hypertension
4. Person with known history of hypertension and/or CVD treatment in the past
5. Person not likely to stay in the area for the required follow-up period of 15 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measure the comparison is hypertension control. This outcome measure will be taken at the completion of 15 months of patient registration. The hypertension control at 15 months will be measured in terms of mean change in systolic blood pressure, i.e. change of mean blood pressure compared to the baseline. The blood pressure measurements at the registration and at completion of 15 months will be taken and recorded by an external expert assessor, not involved in trial implementation and also kept blind to the trial arms (with a mercury apparatus).

Secondary Outcome Measures

Name	Time	Method
1. Glycaemic control<br>2. Cholesterol control and tobacco cessation among the registered hypertension patients<br><br>The glycaemic control and cholesterol control at 15 months will be measured in terms of mean change in HbA1c and change in serum cholesterol respectively. A recognized quality assured laboratory service will be used for HbA1c and serum cholesterol testing at the baseline and 15 months follow-up. In addition to these three key outcome measures, an additional set of process, output and outcome measures will also be selected, through TWG process, for comparing the intervention and control.